-+ 0.00%
-+ 0.00%
-+ 0.00%

Legend Biotech Expects Company-Wide Adjusted Net Profit in 2026

PUBT·11/10/2026 13:17:30
Listen to the news
Legend Biotech Expects Company-Wide Adjusted Net Profit in 2026
  • Legend Biotech expects company-wide profitability in 2026, measured by adjusted net income.
  • Third-quarter adjusted net income reached $55.6 million, versus an adjusted net loss of $18.7 million a year earlier.
  • Revenue rose 32% to $359.5 million, supporting improved operating leverage.
  • CARVYKTI peak annual sales potential exceeds $5 billion; third-quarter net trade sales increased 36% to $710 million.
  • Planned capital expenditures remain modest for ongoing manufacturing capacity expansion.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Legend Biotech Corporation published the original content used to generate this news brief on November 10, 2026, and is solely responsible for the information contained therein.